Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer
Objective: The objective is to learn how Saudi Arabia’s urologists treat patients with Bacillus Calmette–Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) and their choices in management for BCG-naive patients during the BCG shortage. Materials and Methods: A 10-min web-based surve...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Urology Annals |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ua.ua_43_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087019774279680 |
|---|---|
| author | Mohammad Alghafees Mohamad Abou Chakra Abdullah Alkhayal Mohamad Moussa Mohammad Alkhamees Bader Alsaikhan Ahmed Alasker Abdulrahman Alsayyari Abdullah Alsaghyir Ali Alkahtani Michael A. O'Donnell |
| author_facet | Mohammad Alghafees Mohamad Abou Chakra Abdullah Alkhayal Mohamad Moussa Mohammad Alkhamees Bader Alsaikhan Ahmed Alasker Abdulrahman Alsayyari Abdullah Alsaghyir Ali Alkahtani Michael A. O'Donnell |
| author_sort | Mohammad Alghafees |
| collection | DOAJ |
| description | Objective:
The objective is to learn how Saudi Arabia’s urologists treat patients with Bacillus Calmette–Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) and their choices in management for BCG-naive patients during the BCG shortage.
Materials and Methods:
A 10-min web-based survey was sent through the King Saud bin Abdul-Aziz University for Health Sciences’ College of Medicine Clinical Affairs to urologists treating NMIBC based on the Saudi Urologic Association Database.
Results:
The questionnaire was completed by 19 urologists, most of whom (68%) were self-identified as urologic oncologists. In the 6 months before survey administration, the majority of urologists (67% of those surveyed) had treated over five NMIBC patients who had failed BCG therapy. The preferred course of treatment for these patients was a radical cystectomy, as advised by 79% of the participants. Other preferred options were intravesical chemotherapy (16%) and repeat BCG therapy (5%). Clinical trials were never chosen. Sixty percent gemcitabine (Gem), 20% mitomycin C, 10% docetaxel (Doce), and 10% sequential Gem/Doce were rated as the most preferred intravesical chemotherapy regimens used. Saudi urologists were most reluctant to utilize intravesical chemotherapy because of uncertainty about the treatment’s clinical effectiveness (oncological safety) and the absence of specific guidelines from urology societies regarding the use of these drugs. BCG shortages are still a problem in Saudi Arabia, as 79% of respondents reported shortages. Most commonly, during BCG shortages, Saudi urologists rationed BCG to patients with high-risk disease, preferring pT1and/or carcinoma in situ to Ta high grade. The minority (16%) switch to intravesical chemotherapy in these circumstances.
Conclusions:
Saudi urologists have begun employing a bladder-sparing strategy, particularly intravesical chemotherapy, for BCG-unresponsive disease. To properly select treatment for this condition, there is an urgent need to implement initiatives to open clinical trials and provide guideline-based protocols to Saudi Arabia and throughout the Arab world. |
| format | Article |
| id | doaj-art-5c44eb7633a84916a3a7d8fb115344a8 |
| institution | Kabale University |
| issn | 0974-7796 0974-7834 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Urology Annals |
| spelling | doaj-art-5c44eb7633a84916a3a7d8fb115344a82025-02-06T07:30:03ZengWolters Kluwer Medknow PublicationsUrology Annals0974-77960974-78342025-01-01171586310.4103/ua.ua_43_24Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancerMohammad AlghafeesMohamad Abou ChakraAbdullah AlkhayalMohamad MoussaMohammad AlkhameesBader AlsaikhanAhmed AlaskerAbdulrahman AlsayyariAbdullah AlsaghyirAli AlkahtaniMichael A. O'DonnellObjective: The objective is to learn how Saudi Arabia’s urologists treat patients with Bacillus Calmette–Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) and their choices in management for BCG-naive patients during the BCG shortage. Materials and Methods: A 10-min web-based survey was sent through the King Saud bin Abdul-Aziz University for Health Sciences’ College of Medicine Clinical Affairs to urologists treating NMIBC based on the Saudi Urologic Association Database. Results: The questionnaire was completed by 19 urologists, most of whom (68%) were self-identified as urologic oncologists. In the 6 months before survey administration, the majority of urologists (67% of those surveyed) had treated over five NMIBC patients who had failed BCG therapy. The preferred course of treatment for these patients was a radical cystectomy, as advised by 79% of the participants. Other preferred options were intravesical chemotherapy (16%) and repeat BCG therapy (5%). Clinical trials were never chosen. Sixty percent gemcitabine (Gem), 20% mitomycin C, 10% docetaxel (Doce), and 10% sequential Gem/Doce were rated as the most preferred intravesical chemotherapy regimens used. Saudi urologists were most reluctant to utilize intravesical chemotherapy because of uncertainty about the treatment’s clinical effectiveness (oncological safety) and the absence of specific guidelines from urology societies regarding the use of these drugs. BCG shortages are still a problem in Saudi Arabia, as 79% of respondents reported shortages. Most commonly, during BCG shortages, Saudi urologists rationed BCG to patients with high-risk disease, preferring pT1and/or carcinoma in situ to Ta high grade. The minority (16%) switch to intravesical chemotherapy in these circumstances. Conclusions: Saudi urologists have begun employing a bladder-sparing strategy, particularly intravesical chemotherapy, for BCG-unresponsive disease. To properly select treatment for this condition, there is an urgent need to implement initiatives to open clinical trials and provide guideline-based protocols to Saudi Arabia and throughout the Arab world.https://journals.lww.com/10.4103/ua.ua_43_24bacillus calmette–guérinbladder cancerintravesical chemotherapysaudi arabiaurologic oncology |
| spellingShingle | Mohammad Alghafees Mohamad Abou Chakra Abdullah Alkhayal Mohamad Moussa Mohammad Alkhamees Bader Alsaikhan Ahmed Alasker Abdulrahman Alsayyari Abdullah Alsaghyir Ali Alkahtani Michael A. O'Donnell Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer Urology Annals bacillus calmette–guérin bladder cancer intravesical chemotherapy saudi arabia urologic oncology |
| title | Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer |
| title_full | Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer |
| title_fullStr | Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer |
| title_full_unstemmed | Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer |
| title_short | Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer |
| title_sort | saudi urologists treatment pattern for high risk bacillus calmette guerin naive and bacillus calmette guerin unresponsive nonmuscle invasive bladder cancer |
| topic | bacillus calmette–guérin bladder cancer intravesical chemotherapy saudi arabia urologic oncology |
| url | https://journals.lww.com/10.4103/ua.ua_43_24 |
| work_keys_str_mv | AT mohammadalghafees saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT mohamadabouchakra saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT abdullahalkhayal saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT mohamadmoussa saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT mohammadalkhamees saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT baderalsaikhan saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT ahmedalasker saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT abdulrahmanalsayyari saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT abdullahalsaghyir saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT alialkahtani saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer AT michaelaodonnell saudiurologiststreatmentpatternforhighriskbacilluscalmetteguerinnaiveandbacilluscalmetteguerinunresponsivenonmuscleinvasivebladdercancer |